Guwahati, Oct. 29 -- India's national drug price regulator has revised the maximum retail prices of 543 cancer drug brands, with some medicines becoming cheaper by more than 90%.

The National Pharmaceutical Pricing Authority (NPPA) released the revised price list on Wednesday, covering several generic and biosimilar medicines. However, prices of some expensive branded cancer treatments, including Keytruda from MSD Pharma, remain unchanged.

Among the major reductions, the price of one brand of Palbociclib, used to treat certain types of breast cancer, has fallen from Rs 40,421 to Rs 2,270 for the specified pack size.

The cost of Thiotepa, a chemotherapy drug manufactured by Samarth Life Sciences Pvt Ltd, has also dropped from Rs 80,072 ...